tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Little Green Pharma Welcomes Landmark US Move to Reschedule Cannabis

Story Highlights
  • Little Green Pharma hails the US move to reschedule cannabis as a historic federal reform.
  • Company expects Schedule III status to improve sector economics, capital access and long-term growth outlook.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Little Green Pharma Welcomes Landmark US Move to Reschedule Cannabis

Claim 70% Off TipRanks This Holiday Season

Little Green Pharma Ltd. ( (AU:LGP) ) just unveiled an announcement.

Little Green Pharma has highlighted a recent US Executive Order directing the Attorney General to move cannabis from Schedule I to Schedule III, describing it as the most significant federal reform in more than half a century and a key step in the maturation of the global cannabis industry. The company says rescheduling would remove punitive US tax treatment under Section 280E, improve after‑tax cash flows for US operators, lower regulatory and legal risk, and over time enable cheaper capital, greater institutional participation and more M&A activity, while also supporting expanded medical research and deeper integration of cannabis into healthcare systems—developments it believes materially strengthen the long‑term outlook for the global medicinal cannabis sector, including its own growth prospects.

The most recent analyst rating on (AU:LGP) stock is a Buy with a A$0.18 price target. To see the full list of analyst forecasts on Little Green Pharma Ltd. stock, see the AU:LGP Stock Forecast page.

More about Little Green Pharma Ltd.

Little Green Pharma Ltd (ASX:LGP) is a leading global medicinal cannabis company with vertically integrated operations across Europe and Australia. It produces and distributes a diverse portfolio of cannabis-based medicines across Australia and more than a dozen export markets via wholesalers, pharmacies, clinics and GPs, and also operates the Health House distribution business. With three production facilities in Denmark and Australia, including one of Europe’s largest, LGP is among the top three suppliers in Australia and a major supplier into France, Germany and the UK, giving it a strong foothold in high‑growth global medicinal cannabis markets and leveraged exposure for investors.

Average Trading Volume: 240,117

Technical Sentiment Signal: Sell

Current Market Cap: A$38.21M

Find detailed analytics on LGP stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1